Lymphoma, Non-Hodgkin Clinical Trial
— TenatumomabOfficial title:
A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Verified date | January 2018 |
Source | sigma-tau i.f.r. S.p.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.
Status | Terminated |
Enrollment | 2 |
Est. completion date | April 30, 2017 |
Est. primary completion date | April 30, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - 1. Written informed consent. - 2. A patient who has (a) a histologically documented advanced tumor that has relapsed from, or is refractory to, standard treatment and for which no other standard treatment is available and (b) confirmed Tenascin-C expression obtained through a biopsy on at least one reachable tumor lesion. These patients will have failed one or more prior therapeutic line and had assessable and measurable disease expression, but were not considered eligible for other standard approaches with curative intent, as assessed by the Investigator. - 3. Agreement to hemopoietic stem cell collection procedures (the procedure will be performed upon clinical evaluation of the Investigator and if deemed necessary in the interest of the patient). - 4. Male or female =18 years of age - 5. Eastern Cooperative Oncology Group (ECOG), or WHO performance status of = 2 or Karnofsky > 60 - 6. Life expectancy of at least 3 months. - 7. Negative pregnancy test for all women of child-bearing potential. Appropriate contraception (one highly effective method or a combination of acceptable methods) is to be used during the study period and until 90 days after the last follow-up visit (End of Study Visit) - 8. Hematological, thyroid, liver, cardiac and renal function test results = grade 2 toxicity (according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.03 [CTCAE]"), e.g.: Haematology: - Hematocrit = 30% - Hemoglobin = 9.0 g/dl - White blood cell count = 3 x 109/L - Neutrophils > 1.5 x109/L - Platelets = 100x 109/L Thyroid: - Free-Triiodothyronine and Free-Thyroxine = 3 times upper limit of normal or >3 times lower limit of normal. Liver: - Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase = 2.5 times institutional upper limit of normal (ULN) or =5 x ULN in presence of liver metastases. - Bilirubin = 1.5 x ULN or =3 x ULN in presence of liver metastases. Renal: - Urine protein: =30 mg/dl or dipstick: =3 - eGFR=60 ml/min/1.73 m2 (with Chronic kideny disease-Epidemiology collaboration formula) Cardiac • Resting Ejection Fraction (EF) = 50% Exclusion Criteria: - 1. Known hypersensitivity to Tenatumomab, Iodine or any excipient. - 2. Active infection at screening or history of severe infection within the previous 2 months, if considered clinically relevant by the Investigator. - 3. Positive test to Human Immunodeficiency Virus (HIV) and/or chronically active Hepatitis B or C. - 4. Patients with primary Central nervous system tumor or cerebral metastases. - 5. Administration of another investigational medicinal product within 45days before the screening period. - 6. Previous treatment with any radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide used prior to the administration of study drug. - 7. History of somatic or psychiatric disease/condition that may interfere with the objectives of the study. - 8. Major illness, trauma, or surgery within 2 weeks before the screening period, if considered clinically significant by the Investigator. - 9. Patient who underwent chemotherapy and/or radiation therapy and/or treatments with biologics (which are not to be of murine origin) within 4 weeks before the screening period. - 10. Women who are breast feeding, due to the potential risk of damage to the infant. - 11. Men unwilling to use appropriate contraceptive methods during the study and up to 90 days after the last follow-up visit (End of Study Visit). - 12. Bladder catheterization cannot be performed, or the patient is unwilling to be catheterized if necessary. - 13. Murine antibodies treated patients. It is at the discretion of the Investigator to exclude patients who have worsened considerably from screening to Day -1. |
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonnie | Bordeaux | |
France | Centre Leon Berard | Lyon | |
France | Icm Val D'Aurelle | Montpellier | |
Italy | Istituto Nazionale Dei Tumori Irccs - Fondazione "G. Pascale" | Naples | |
Italy | University of Study of Pisa | Pisa | |
Italy | S. Maria Nuova Hospital - Irccs | Reggio Emilia | |
Italy | Humanitas Clinical Institute | Rozzano Mi |
Lead Sponsor | Collaborator |
---|---|
sigma-tau i.f.r. S.p.A. | Medpace, Inc. |
France, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Tumor response | Tumor response according to Response Evaluation Criteria in Solid Tumors RECIST V 1.1 or PERCIST | 1 year | |
Primary | Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03) | no more details necessary | up to six weeks | |
Secondary | Adverse Events | no more details necessary | up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03484702 -
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Completed |
NCT06190457 -
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
|
||
Completed |
NCT02369016 -
Phase III Copanlisib in Rituximab-refractory iNHL
|
Phase 3 | |
Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
Withdrawn |
NCT00319332 -
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
|
Phase 3 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Completed |
NCT00141297 -
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT00322842 -
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
|
Phase 2 | |
Completed |
NCT02509039 -
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
|
Phase 1 | |
Completed |
NCT01573000 -
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
Completed |
NCT00268203 -
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT03289182 -
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
|